Clinical Trial Update: A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208) [Phase 1, Phase 2]

View source ↗

Summary

Trial update for Epacadostat and Nivolumab in combination with other therapies in advanced/metastatic solid tumors; study terminated with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumor

Drugs mentioned

• Epacadostat (epacadostat)
• nivolumab (nivolumab)

Snippet

Sponsor: Incyte Corporation | Conditions: Solid Tumors | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2022-02-28